.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG10_Inebilizumab.Inebilizumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG10_Inebilizumab.Inebilizumab| name: | Inebilizumab |
| ATC code: | L04AG10 | route: | intravenous |
| n-compartments | 2 |
Inebilizumab is a humanized monoclonal antibody directed against CD19, a protein expressed on B cells. It is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. It acts by depleting B cells involved in autoimmune pathophysiology.
Pharmacokinetic parameters were reported for adult NMOSD patients receiving intravenous inebilizumab in clinical trials.
Yan, L, et al., & Rees, WA (2022). Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis. Clinical pharmacokinetics 61(3) 387–400. DOI:10.1007/s40262-021-01071-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34718986
Yan, L, et al., & Rees, WA (2022). Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders. British journal of clinical pharmacology 88(8) 3803–3812. DOI:10.1111/bcp.15332 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35332558
Ohmachi, K, et al., & Okamura, J (2019). A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma. International journal of hematology 109(6) 657–664. DOI:10.1007/s12185-019-02635-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30915717